Protein Biomarker Signatures in Precision Diagnostics of Cancer

Henrik Winther, Carl Borrebaeck

Research output: Chapter in Book/Report/Conference proceedingBook chapterResearchpeer-review

Abstract

Early diagnosing and patient individualized biomarker profiling are two key elements for curative interventions within cancer. Detecting cancer, when the tumor is still localized, allows for a more efficient treatment-either through surgery alone or with systemic therapies, treating a naïve and less heterogeneous tumor cell population. Developing tumors consist of complex and stage-dependent genetic heterogenous cell-populations. Each cell clone can have different mutation profiles and various protein pathways activated, which often hinders single targeted therapies to embrace all the heterogenous clonalities and therefore leads to drug inefficiency, resistance, and disease relapse. Proteomics and genomics technologies have been used intensively over the last two decades in the revealing of ever more clinical relevant proteins and genetic mutations and alterations. Protein-based profiling assays used for diagnostic, prognostic, predictive, and monitoring purposes are obligated to follow the country-by-country regulatory standards required by authorities with regard to medical devices.

Original languageEnglish
Title of host publicationAdvances in Medical Imaging, Detection, and Diagnosis
PublisherJenny Stanford Publishing
Pages487-505
Number of pages19
ISBN (Electronic)9781000602043
ISBN (Print)9789814877466
DOIs
Publication statusPublished - 2023 Jan 1

Subject classification (UKÄ)

  • Cancer and Oncology

Free keywords

  • area under the curve (AUC)
  • assay workflow
  • bioinformatics
  • biomarker
  • biopsies
  • cancer
  • China Food and Drug Administration (CFDA)
  • circulating tumor DNA (ctDNA)
  • clinical accuracy
  • cross-validation
  • diagnostic
  • enzyme-linked immunosorbent assay (ELISA)
  • European Medicines Agency (EMA)
  • genomics
  • hands-on-time (HOT)
  • high-density antibody microarrays
  • immunohistochemistry
  • in vitro diagnostic (IVD)
  • limit of detection
  • limit of quantification
  • mass spectrometry (MS)
  • medical device
  • microarray
  • multiple reaction monitoring (MRM)
  • multiplexing
  • next-generation sequencing (NGS)
  • premarket approval
  • profiling
  • protein
  • proteomics
  • reaction monitoring
  • receiver operating characteristic
  • regulatory considerations
  • responsiveness
  • selected reaction monitoring (SRM)
  • serum
  • specificity
  • turnaround time
  • US Food and Drug Administration (FDA)

Fingerprint

Dive into the research topics of 'Protein Biomarker Signatures in Precision Diagnostics of Cancer'. Together they form a unique fingerprint.

Cite this